<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Medical research platform Medeloop raised USD 15.5 million in Series A funding led by Inovia Capital, with participation from Icon Ventures and existing investors General Catalyst and Maven Ventures. This brings the total funds raised by the company to USD 23.5 million.
      </p>
    </li>
    <li>
      <p>
        The funding will be used to expand Medeloop's end-to-end AI-powered platform, which includes tools for grant applications, clinical studies management, data analytics, and manuscript publication.
      </p>
    </li>
    <li>
      <p>
        Founded by AI experts at Stanford, Medeloop's platform can perform analyses up to 1,000 times faster than traditional methods by transforming data into a graph database and enriching it with connections to external datasets.
      </p>
    </li>
    <li>
      <p>
        <b>Analyst QuickTake: </b>
        The company last raised funding just over a year ago in 
        <a href="https://sp-edge.com/updates/22082">
          September 2023
        </a>
        ; at the time, the funds were used to launch the company's platform. Since then, the company has partnered with Quebec research center Mila in 
        <a href="https://sp-edge.com/updates/27351">
          March
        </a>
         of this year to integrate AI into health research and expedite clinical trials. This funding round indicates that the company and its offerings are now established and are ready for expansion.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.globenewswire.com/news-release/2024/11/13/2980200/0/en/Medeloop-Secures-15-5-Million-in-Series-A-Funding-to-Accelerate-Medical-Research.html">
      Press release
    </a>
  </p>
  <p>
    <a href="https://hitconsultant.net/2024/11/13/medeloop-raises-15-5m-for-ai-driven-medical-research-platform/">
      HIT Consultant
    </a>
  </p>
  <p>
  </p>
</div>


Clinical Trial Technology

ANALYST_QUICK_TAKE

<div>
 
 <p>Medeloop, a medical research platform, has secured USD 15.5 million in a Series A funding round. Inovia Capital led the funding, which also saw participation from Icon Ventures, General Catalyst, and Maven Ventures. The latest investment takes Medeloop's total funding to USD 23.5 million.</p>
 <p>The company will deploy the new funds to expand its end-to-end AI-powered platform. The platform encompasses various tools, including those for grant applications, clinical studies management, data analytics, and manuscript publication.</p>
 <p>Stanford's AI experts established Medeloop. The company's platform is capable of performing analysis up to 1000 times quicker than traditional methods. It achieves this speed by converting data into a graph database and enhancing it with links to external datasets.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> The company last raised funding just over a year ago in <a href="https:<br>
//sp-edge.com/updates/22082"> September 2023 </a> ; at the time, the funds were used to launch the company's platform. Since then, the company has partnered with Quebec research center Mila in <a href="https:<br>
//sp-edge.com/updates/27351"> March </a> of this year to integrate AI into health research and expedite clinical trials. This funding round indicates that the company and its offerings are now established and are ready for expansion.</p>

Medeloop raises USD 15.5 million in Series A funding to expand AI platform

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>

<p>Formation Bio, Sanofi, and OpenAI have partnered to create "Muse," an AI-based tool aimed at enhancing patient recruitment for clinical trials.</p>
<p>This tool uses scientific literature and real-world evidence to produce extensive research, recruitment strategies, and patient documents in minutes rather than months. Initially, Sanofi will implement Muse in Phase III Multiple Sclerosis trials.</p>
<p>Muse hopes to combat the low rate of clinical trial participation (which is less than 10% of patients) by developing customised strategies for varied patient groups, taking into account regulatory guidelines and assuring data privacy standards are met.</p>
 
</div>

Formation Bio partners with Sanofi and OpenAI to develop an AI-powered clinical trial recruitment tool

<div>
 
 <p>Ontada, a McKesson business, has formed a partnership with health data platform Datavant with the goal of improving access to oncology research data. The collaboration seeks to expedite the process of oncology innovation and drug development by granting life science companies quicker and more advanced access to Ontada's comprehensive real-world data set, which includes information on 2.4 million patients across over 80 tumor types. Through Datavant's secure health data ecosystem, the partnership also allows researchers to connect Ontada's data with other available datasets.</p>
 <p>The partnership intends to leverage data obtained from The US Oncology Network by Ontada. This data is particularly significant given that one in five cancer patients in the U.S. receive their treatment within this network. The network's extensive community cancer care insights can guide researchers in developing new cancer therapies and delivery models for care.</p>
 
</div> <p><b>Analyst Quicktake:<br>
 </b> This marks the second partnership agreement Ontada signed this year. Earlier, in <a href="https:<br>
//sp-edge.com/updates/34950"> October </a> , Ontada partnered with Microsoft to use Azure AI to process unstructured oncology data. By partnering with Datavant, it appears Ontada is adopting a strategy of expanding its platform's capabilities and market reach through partnerships.</p>

Ontada partners with Datavant to enhance access to oncology real-world data

<div>

<p>Medable Inc., a company specializing in clinical development technology, has announced the launch of Medable AI. This is a suite of GenAI capabilities that will be incorporated into its Studio platform. The service is set to be available from December 2024 and is designed to streamline digital and decentralized clinical trials for research organizations and sponsors.</p>

<p>The AI suite provides various features including automated eCOA creation, which digitizes existing outcome assessments, a user interface similar to ChatGPT for editing assessments, and the ability to generate assessments on a large scale. Based on initial metrics undertaken, this suite is capable of completing multiple outcome assessments in only half an hour, a task that would normally require multiple days.</p>

<p>Medable asserts that these new AI capabilities will lead to reduced time to First Patient In (FPI), streamline workflows, and allow users to have increased transparency and control over trial creations. In the future, Medable has plans to expand these AI capabilities across its entire platform.</p>

</div> <p><b>Analyst QuickTake:<br>
 </b> This is Medable's second new offering this year. Earlier, in <a href="https:<br>
//sp-edge.com/updates/32647"> August </a> , the company launched Medable Studio, an all-in-one application for configuring, translating, validating, and launching electronic clinical outcome assessment (eCOA) Plus solutions (which include eCOA, e-consent, televisions , and sensors) into clinical trials. With Medable AI's launch, the company is potentially looking to expand its market share through internal product innovation.</p>

Medable launches AI suite for clinical trial management

<div>

<p>Research Grid, a clinical trial automation platform, has successfully raised USD 6.5 million in seed funding. The funding was led by Fuel Ventures and saw participation from several other firms including Ada Ventures, Arve Capital, Morgan Stanley Inclusive Ventures Lab, Plug and Play Ventures, Arāya Ventures, Atomico Angels, and Ascension Ventures.</p>
<p>The funds will be allocated towards various sectors within the company such as research and development, AI automation development, expansion of the engineering team, enhancement of marketing and sales operations, and increasing the company's footprint in the intensive US and Asian markets.</p>
<p>Research Grid's products, namely the Inclusive and TrialEngine platforms, assist operators of clinical trials in managing the entire lifecycle of these trials - right from pretrial operations to their conclusion. The vast access provided by the Inclusive platform expands up to 91,000 global communities and covers a range of around 2,050 medical conditions. There have been positive reviews reported by customers who had noticeable efficiency gains (98%), cost savings (45%), and a considerable increase in patient engagement by 145%.</p>

</div>

Research Grid raises USD 6.5 million in seed funding to enhance clinical trials

<div>
 
 <p>The National Cancer Center (NCC) Japan, Precision Medicine Asia (PREMIA), and Paradigm Health are teaming up to initiate LC-SCRUM-CD, a broad-scaled clinical trial network for cancer research in Japan. This partnership will utilize LC-SCRUM-Asia's existing network of over 150 hospitals, specifically for cancer genomic testing.</p>
 <p>PREMIA will handle the data platform management, whilst Paradigm brings to the table their comprehensive clinical trial platform. The alliance aims to increase the frequency of international pharmaceutical-sponsored trials in Japan, simultaneously alleviating the operational stress on healthcare providers.</p>
 <p>This initiative is a build upon NCC Hospital East's clinical trial capabilities, with already existing annual studies exceeding 500. The collaboration will facilitate a more efficient patient recruitment for clinical trials by amalgamating the results from genetic analysis with clinical data.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> This is the second partnership Paradigm has established in Japan. Earlier this year, Paradigm <a href="https:<br>
//sp-edge.com/updates/32922"> partnered with Fujitsu </a> , a global technology company, to improve clinical trials and address drug loss in Japan. The company appears to be continuing its global expansion strategy, focusing on Japan.</p>

NCC Japan partners with PREMIA and Paradigm to establish nationwide cancer clinical trial network

<div>

 <p>H1, a healthcare data and analytics provider, has upgraded its Trial Landscape platform by incorporating diversity data for over 34 million patients in England and introducing an AI-powered Site Rescue function. These enhancements are offered to Trial Landscape clients having the worldwide data package.</p>
 
 <p>The improved platform now contains race and ethnicity data from UK patients and includes Site Rescue, an AI-enabled tool that identifies healthcare providers, sites, and principal investigators based on past performance data. The platform supports sponsors in designing inclusive trials and fulfilling regulatory demands from organizations like the FDA, HRA, and MHRA.</p>
  
 <p>In H1's view, the advanced platform will assist in tackling the problem of 80% of clinical trials not meeting diversity goals, enable sponsors to conduct trials that more accurately represent real-world populations, and decrease delays in trial completion through ideal site selection.</p>

</div>

H1 adds UK patient diversity data to Trial Landscape platform

<div>
 
 <p>Signant Health has formed a partnership with SPRIM PRO, a Contract Research Organization that specializes in biopharmaceutical and nutrition research. Their collaboration is focused on improving clinical trial technology solutions.</p>
 <p>This partnership will allow SPRIM PRO to use Signant's SmartSignals Unified Platform, which incorporates various features such as EDC, eCOA, eConsent, RTSM, and telemedicine capabilities. The aim of this collaboration is to assist SPRIM PRO's decentralized, hybrid, and onsite clinical trials via integrated technologies. It will accommodate for early and late-phase studies, offer flexible ePRO deployment options and provide support for global trial execution.</p>
 
</div>

Signant Health partners with SPRIM PRO to provide e-clinical solutions for specialized research

<div>
 
 <p>Decentralized clinical trial solutions provider, Medable, has entered into a partnership with Google Cloud, making its platform accessible via Google Cloud Marketplace. This collaboration puts together the clinical trial technology of Medable and the infrastructure and AI capabilities of Google Cloud, making trial processes more streamlined. Life sciences companies stand to benefit from simple access, consolidated billing, and cost optimization through Google Cloud Marketplace. As of October 2024, Medable's platform has been successfully implemented in over 300 trials in 60 countries, serving more than 1 million patients.</p>
 
</div> <p><b>Analyst QuickTake:<br>
</b> Earlier this year, Medable <a href="https:<br>
//sp-edge.com/updates/32647"> launched Medable Studio </a> , an all-in-one application for configuring, translating, validating, and launching electronic clinical outcome assessment (eCOA) Plus solutions (which include eCOA, e-consent, televisits, and sensors) into clinical trials. Through its partnership with Google Cloud, the company will be able to expand access to its solutions, including Medable Studio, further increasing its market share in the clinical trial space.</p>

Medable partners with Google Cloud to offer decentralized clinical trial platform on marketplace

<div>
 
 <p>Dyania Health, an AI based healthcare data firm, managed to gather USD 10M in Series A funding with leading support from HealthX Ventures. Other participants included Tech Square Ventures, Cleveland Clinic Ventures along with the previous investors. This inflow of funds has brought the company's total fund pool to a whopping figure of USD 15.3M.</p>
 <p>These funds are earmarked for various growth initiatives, including the expansion of AI capabilities within the company. Additionally, they will further develop their own Synapsis AI platform and upscale the operational bandwidth, satisfying the burgeoning demand from healthcare institutions and biopharmaceutical companies. </p>
 <p>Dyania's Synapsis AI platform works by processing both unstructured and structured healthcare data, within the firewalls of the healthcare systems. The platform does all this while maintaining supreme compliance with HIPAA and GDPR. By performing complex medical chart reviews in under a second, the platform helps healthcare and life science organizations extract valuable insights from unstructured clinical data. It's interesting to note that Cleveland Clinic was among the early adopters of this platform.</p>
 
</div>

All Updates

Medeloop raises USD 15.5 million in Series A funding to expand AI platform

Formation Bio partners with Sanofi and OpenAI to develop an AI-powered clinical trial recruitment tool

Ontada partners with Datavant to enhance access to oncology real-world data

Medable launches AI suite for clinical trial management

Research Grid raises USD 6.5 million in seed funding to enhance clinical trials

NCC Japan partners with PREMIA and Paradigm to establish nationwide cancer clinical trial network

H1 adds UK patient diversity data to Trial Landscape platform

Signant Health partners with SPRIM PRO to provide e-clinical solutions for specialized research

Medable partners with Google Cloud to offer decentralized clinical trial platform on marketplace

Dyania Health raises USD 10 million in Series A funding from HealthX Ventures

Clinical Trial Technology

Medeloop raises USD 15.5 million in Series A funding to expand AI platform

Contact us